Monopar Therapeutics (MNPR) Director Kim R. Tsuchimoto Sells Shares

What Happened
Kim R. Tsuchimoto, a director of Monopar Therapeutics (MNPR), sold a total of 4,090 shares in multiple open-market transactions on August 26, 2026, generating approximately $455,567 in proceeds. The individual dispositions reported were: 485 shares at $108.83 ($52,783); 615 shares at $109.56 ($67,379); 700 shares at $110.65 ($77,455); 1,098 shares at $111.84 ($122,800); 602 shares at $112.93 ($67,984); and 590 shares at $113.84 ($67,166). These were sales (not purchases), which are commonly routine cashing‑out transactions rather than a direct bullish signal.

Key Details

• Transaction date: 2026-08-26; Form 4 filed 2026-08-27 (timely filing).
• Total shares sold: 4,090; total proceeds: ~ $455,567.
• Prices shown are weighted averages; execution price ranges across the lots were approximately:
  • Lot 1: ~$108.07–$109.05
  • Lot 2: ~$109.07–$110.04
  • Lot 3: ~$110.14–$111.05
  • Lot 4: ~$111.30–$112.27
  • Lot 5: ~$112.30–$113.25
  • Lot 6: ~$113.35–$114.34
• Reported as executed pursuant to a Rule 10b5-1 trading plan established 05/27/2026. The filing notes it can supply specific per-trade prices on request.
• Shares owned after the transactions are not specified in the provided excerpt — see the full Form 4 for post-transaction holdings.

Context
A Rule 10b5-1 plan is a pre-arranged trading program that allows insiders to sell shares at scheduled times regardless of any subsequent material nonpublic information; sales under such plans are often viewed as routine. For retail investors, purchases by insiders tend to be more indicative of conviction than scheduled sales; these transactions primarily show liquidity taken by a director rather than a clear signal about company prospects.